IP Library Granted Patent US 9,447,380
Granted Patent B2
US 9,447,380 · App. 13/957,987 · Granted Sep 20, 2016

Non-static suspension culture of cell aggregates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,447,380
App. No.
13/957,987
Granted
Sep 20, 2016
Kind
B2
Abstract

The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.

Claims (9)

1. A method for making a cell culture composition comprising aggregates of stem cells that are not embryonic stem cells, embryonic germ cells, or germ cells, wherein the aggregates are in non-static cell culture and wherein the cell density ranges from about 5×10 4 cells/ml to about 10 8 cells/ml, the method comprising inoculating a cell culture with stem cell aggregates and expanding the inoculated aggregates so that expansion produces a cell density of about 5×10 4 cells/ml to about 10 8 cells/ml.

2. The method of claim 1 wherein the cells that are not embryonic stem cells, embryonic germ cells, or germ cells can differentiate into cell types of at least two of the endodermal, ectodermal and mesodermal embryonic lineages.

3. The method of claim 1 wherein the non-embryonic stem cells, non-embryonic germ cells, non-germ cells express oct4, are not transformed, and have a normal karyotype.

4. The method of claim 1 wherein the non-embryonic stem cells, non-embryonic germ cells, non-germ cells are not transformed and have a normal karyotype, and wherein, prior to aggregation, the cells have undergone about 40 cell doublings in culture.

5. The method of claim 1 wherein the non-embryonic stem cells, non-embryonic germ cells, non-germ cells express telomerase, are not transformed, and have a normal karyotype.

6. The method of claim 1 wherein the non-embryonic stem cells, non-embryonic germ cells, non-germ cells are positive for one or more of oct3/4, telomerase, rex-1, rox-1, nanog, GATA6 and sox-2.

7. The method of any of claims 1 and 2 - 6 wherein expansion is non-adherent.

8. The method of any of claims 1 and 2 - 6 wherein the non-embryonic stem cells, non-embryonic germ cells, non-germ cells are derived from bone marrow.

9. The method of claim 7 wherein the non-embryonic stem cells, non-embryonic germ cells, non-germ cells are derived from bone marrow.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 067606/0139 →
RELEASE OF SECURITY INTEREST Recorded May 29, 2024
From: HEALIOS K.K.
To: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
Reel/Frame 067566/0638 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 1, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 066435/0775 →